Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00124267 |
Recruitment Status : Unknown
Verified July 2005 by Makerere University.
Recruitment status was: Active, not recruiting
First Posted : July 27, 2005
Last Update Posted : August 4, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cerebral Malaria | Drug: Intrarectal quinine | Phase 3 |
Cerebral malaria is the most lethal complication of P.falciparum infection with a mortality rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral malaria. However its administration is often not feasible due to lack of simple equipment or trained staff. When referral is not possible, a viable alternative is needed. The intrarectal route is of interest in children since it is painless and simple. A few studies in Francophone Africa have reported clinical efficacy and tolerance of intrarectal quinine. Although the studies were randomized trials, they were not blinded and did not use the WHO definition of cerebral malaria as selection criteria.
The current study aims to establish whether intrarectal quinine is as effective and as safe as intravenous quinine in the treatment of childhood cerebral malaria.
To address the shortcomings of the Francophone African studies, the investigators have designed a randomized, double blind placebo controlled clinical trial to include patients who meet the WHO definition of cerebral malaria.
Hypothesis:
Intrarectal quinine (15mg/kg every 8 hours) given to children with cerebral malaria, will lead to a shorter parasite clearance time (39.9 hours) than intravenous quinine (55.0 hours).
The investigators calculated a sample size of 54 patients in each group for 90% power and 95% confidence. In the calculation, the researchers assumed that the children receiving intrarectal quinine would have a mean parasite clearance time of 39.9 (SD 24.3) hours and those receiving intravenous quinine would have a mean parasite clearance time of 55.0(SD 24.3) hours (27.5% effect size), according to a study by Aceng, Byarugaba and Tumwine in the same hospital.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 108 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial |
Study Start Date : | September 2003 |
Study Completion Date : | January 2004 |
- Parasite clearance time
- Fever clearance time
- Coma recovery time
- Time to sit unsupported
- Time to begin oral intake
- Mortality
- Neurological sequelae
- Adverse drug events

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Months to 5 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children aged 6 months to 5 years admitted to Mulago hospital during the study period who satisfy the World Health Organization (WHO) case definition of cerebral malaria (Unarousable coma lasting more than 30 minutes after a seizure, with peripheral asexual P.falciparum parasitaemia and absence of other causes of coma) and whose caretakers give informed consent.
Exclusion Criteria:
- Patients with diarrhea (more than 4 motions/24 hours)
- Any recent anal pathology (such as rectal bleeding, rectal prolapse)
- Documented quinine treatment in previous 48 hours.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00124267
Uganda | |
Mulago Hospital | |
Kampala, Uganda, 7051 |
Principal Investigator: | Jane Achan, MBChB | Department of Paediatrics and Child Health, Makerere University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00124267 |
Other Study ID Numbers: |
2001/HD11/524/RQ |
First Posted: | July 27, 2005 Key Record Dates |
Last Update Posted: | August 4, 2005 |
Last Verified: | July 2005 |
Cerebral malaria intra-rectal quinine |
children Uganda efficacy safety |
Malaria Malaria, Cerebral Protozoan Infections Parasitic Diseases Infections Vector Borne Diseases Central Nervous System Protozoal Infections Central Nervous System Parasitic Infections Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases Quinine |
Antimalarials Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Muscle Relaxants, Central Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents Analgesics, Non-Narcotic Analgesics Sensory System Agents |